Pfizer Inc. (PFE)

Shares of Teva -- a generic-drug maker with a history of losses and high leverage -- have rallied strongly. Pfizer and Merck, which make branded drugs, are financially strong and are rebuilding their drug pipelines.

Teladoc and Pfizer have both faced challenges over the past few years. While the latter has a clear path to recovery, the former doesn't seem to.

Stock News Tech-led selloff caps tough week: US stocks fell as investors rotated out of mega-cap tech after Broadcom (AVGO) and Oracle (ORCL) stoked AI-spending

FDA officials are weighing a black box warning for Covid vaccines, a proposal that has drawn strong criticism from outside experts citing lack of evidence.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to brin.

Pfizer's coronavirus-related sales have fallen sharply -- and they may decline even further next year. The company is developing some promising products, including a flu vaccine and a weight loss therapy.

Bristol Myers Squibb's stock is down 35% from its 2022 highs as it faces patent cliffs. Pfizer is down 55% from its 2021 highs as it contends with similar challenges.

The Dividend Harvesting Portfolio remains up 32.60% on invested capital, yielding 8.02%, despite a temporary dip in dividend income from the MSTY reverse split. A dovish Fed rate cut and bullish GDP projections support expectations for a year-end market rally, favoring income-generating, rate-sensitive holdings. Recent capital was allocated to AMLP for high-yield, fee-based energy exposure, and to VZ, citing turnaround potential and robust EBITDA.

Pfizer's Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive metastatic breast cancer who had responded well to initial treatment, according to results of a late-stage trial.

Investors watching the global biotech race may be sensing a shift after Moderna (MRNA) co-founder and chairman Noubar Afeyan suggested the US could be losing mo

The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.

Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.

Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.

JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death amon.

Arrow Capital Pty Ltd purchased a new position in Pfizer Inc. (NYSE: PFE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 192,329 shares of the biopharmaceutical company's stock, valued at approximately $4,662,000. Pfizer makes up about 3.4% of